B cell Phenotype (cells/μL) CFS Patients Non-fatigued controls P-value
Naive 86.62 ± 21.14 113.81 ± 23.05 0.43
T1/2 10.61 ± 2.75 16.45 ± 3.52 0.56
Maturenaive 11.42 ± 2.75 14.85 ± 5.23 0.42
T3 59.24 ± 15.22 72.29 ± 16.05 0.51
Non-switched 4.85 ± 2.30 4.03 ± 2.53 0.53
Doublenegative 223.31 ± 30.78 236.72 ± 29.78 0.44
switched 137.37 ± 12.97 113.21 ± 14.73 0.47
Plasmablast 96.66 ± 9.03 88.56 ± 11.05 0.49
HLA-DRplasma cells 90.61 ± 8.46 78.45 ± 9.79 0.52
Plasmacells 1.45 ± 0.23 1.84 ± 1.9 0.61
 
B cell Receptors (%) CFS Patients Non-fatigued controls P-value
Total CD79α+β+ (BCR) 58.99 ± 4.46 58.72 ± 5.92 0.74
CD40L+ 4.01 ± 0.60 4.68 ± 1.23 0.65
BCR IgE+ 3.05 ± 1.30 2.62 ± 1.87 0.9
BCR IgA+ 54.02 ± 4.02 50.47 ± 5.24 0.83
BCR IgD+ 7.24 ± 3.21 9.76 ± 3.24 0.48
*CD - Cluster of Differentiation, Ig – Immunoglobulin; HLA – Human Leucocyte Antigen; T1/2 – transitional 1 and 2; T3 – transitional 3, BCR – B cell receptor complex.
Table 3: Distribution of B cell phenotypes and receptors in CFS patients and non-fatigued controls.